A detailed history of Krane Funds Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Krane Funds Advisors LLC holds 6,039 shares of GILD stock, worth $402,740. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,039
Previous 5,529 9.22%
Holding current value
$402,740
Previous $447,000 1.12%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 16, 2024

BUY
$71.58 - $87.29 $36,505 - $44,517
510 Added 9.22%
6,039 $442,000
Q4 2023

Feb 14, 2024

BUY
$73.27 - $83.09 $405,109 - $459,404
5,529 New
5,529 $447,000
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $8,133 - $9,276
107 Added 2.72%
4,047 $312,000
Q1 2023

May 12, 2023

SELL
$77.31 - $88.08 $207,345 - $236,230
-2,682 Reduced 40.5%
3,940 $325,000
Q4 2022

Feb 10, 2023

SELL
$62.32 - $89.47 $52,037 - $74,707
-835 Reduced 11.2%
6,622 $568,000
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $10,240 - $11,697
-172 Reduced 2.25%
7,457 $460,000
Q2 2022

Aug 11, 2022

SELL
$57.72 - $65.01 $58,874 - $66,310
-1,020 Reduced 11.79%
7,629 $472,000
Q1 2022

May 11, 2022

BUY
$57.92 - $72.58 $75,411 - $94,499
1,302 Added 17.72%
8,649 $514,000
Q4 2021

Feb 10, 2022

SELL
$64.88 - $73.64 $25,043 - $28,425
-386 Reduced 4.99%
7,347 $533,000
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $51,376 - $55,429
-759 Reduced 8.94%
7,733 $540,000
Q2 2021

Aug 12, 2021

BUY
$63.47 - $69.35 $134,873 - $147,368
2,125 Added 33.38%
8,492 $585,000
Q1 2021

May 14, 2021

BUY
$60.0 - $68.46 $117,060 - $133,565
1,951 Added 44.18%
6,367 $411,000
Q4 2020

Feb 11, 2021

BUY
$56.65 - $64.55 $250,166 - $285,052
4,416 New
4,416 $257,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $83.6B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Krane Funds Advisors LLC Portfolio

Follow Krane Funds Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Krane Funds Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krane Funds Advisors LLC with notifications on news.